Pharmaron Beijing Co Ltd
SZSE:300759
Income Statement
Earnings Waterfall
Pharmaron Beijing Co Ltd
Revenue
|
11.5B
CNY
|
Cost of Revenue
|
-7.4B
CNY
|
Gross Profit
|
4.1B
CNY
|
Operating Expenses
|
-2.3B
CNY
|
Operating Income
|
1.8B
CNY
|
Other Expenses
|
-184.2m
CNY
|
Net Income
|
1.6B
CNY
|
Income Statement
Pharmaron Beijing Co Ltd
Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||
Revenue |
2 713
N/A
|
2 908
+7%
|
3 089
+6%
|
3 274
+6%
|
3 499
+7%
|
3 757
+7%
|
3 953
+5%
|
4 314
+9%
|
4 717
+9%
|
5 134
+9%
|
5 664
+10%
|
6 226
+10%
|
6 849
+10%
|
7 444
+9%
|
8 057
+8%
|
8 793
+9%
|
9 545
+9%
|
10 266
+8%
|
10 887
+6%
|
11 272
+4%
|
11 424
+1%
|
11 538
+1%
|
|
Gross Profit | |||||||||||||||||||||||
Cost of Revenue |
(1 878)
|
(1 958)
|
(2 110)
|
(2 229)
|
(2 349)
|
(2 424)
|
(2 582)
|
(2 737)
|
(2 943)
|
(3 215)
|
(3 577)
|
(3 945)
|
(4 382)
|
(4 768)
|
(5 249)
|
(5 739)
|
(6 164)
|
(6 502)
|
(6 909)
|
(7 152)
|
(7 355)
|
(7 422)
|
|
Gross Profit |
836
N/A
|
950
+14%
|
979
+3%
|
1 046
+7%
|
1 151
+10%
|
1 333
+16%
|
1 371
+3%
|
1 577
+15%
|
1 774
+12%
|
1 919
+8%
|
2 087
+9%
|
2 281
+9%
|
2 467
+8%
|
2 676
+8%
|
2 808
+5%
|
3 054
+9%
|
3 381
+11%
|
3 764
+11%
|
3 978
+6%
|
4 120
+4%
|
4 069
-1%
|
4 116
+1%
|
|
Operating Income | |||||||||||||||||||||||
Operating Expenses |
(430)
|
(500)
|
(508)
|
(529)
|
(562)
|
(627)
|
(638)
|
(679)
|
(719)
|
(832)
|
(878)
|
(935)
|
(1 059)
|
(1 166)
|
(1 258)
|
(1 473)
|
(1 697)
|
(2 042)
|
(2 141)
|
(2 264)
|
(2 285)
|
(2 331)
|
|
Selling, General & Administrative |
(389)
|
(432)
|
(486)
|
(502)
|
(535)
|
(541)
|
(606)
|
(653)
|
(691)
|
(720)
|
(819)
|
(857)
|
(954)
|
(978)
|
(1 146)
|
(1 353)
|
(1 532)
|
(1 641)
|
(1 886)
|
(1 949)
|
(1 965)
|
(1 767)
|
|
Research & Development |
(24)
|
(25)
|
(34)
|
(44)
|
(51)
|
(54)
|
(75)
|
(79)
|
(89)
|
(91)
|
(114)
|
(127)
|
(146)
|
(135)
|
(162)
|
(171)
|
(219)
|
(261)
|
(320)
|
(381)
|
(402)
|
(419)
|
|
Depreciation & Amortization |
0
|
(62)
|
0
|
0
|
0
|
(73)
|
0
|
0
|
0
|
(88)
|
0
|
0
|
0
|
(116)
|
0
|
0
|
0
|
(196)
|
0
|
0
|
0
|
(241)
|
|
Other Operating Expenses |
(17)
|
19
|
12
|
17
|
24
|
42
|
44
|
53
|
61
|
67
|
54
|
49
|
41
|
63
|
50
|
50
|
55
|
56
|
65
|
66
|
82
|
96
|
|
Operating Income |
406
N/A
|
450
+11%
|
471
+5%
|
516
+10%
|
589
+14%
|
707
+20%
|
733
+4%
|
898
+22%
|
1 055
+18%
|
1 087
+3%
|
1 209
+11%
|
1 346
+11%
|
1 408
+5%
|
1 510
+7%
|
1 550
+3%
|
1 580
+2%
|
1 684
+7%
|
1 723
+2%
|
1 838
+7%
|
1 856
+1%
|
1 784
-4%
|
1 785
+0%
|
|
Pre-Tax Income | |||||||||||||||||||||||
Interest Income Expense |
(59)
|
(55)
|
(59)
|
(69)
|
(75)
|
(75)
|
(35)
|
95
|
108
|
244
|
286
|
119
|
231
|
405
|
403
|
414
|
249
|
(277)
|
(36)
|
(0)
|
11
|
14
|
|
Non-Reccuring Items |
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(7)
|
(7)
|
(8)
|
(8)
|
(1)
|
(1)
|
(1)
|
(2)
|
244
|
(1)
|
(1)
|
0
|
48
|
|
Total Other Income |
15
|
0
|
(2)
|
(3)
|
(7)
|
1
|
(14)
|
(14)
|
(14)
|
(5)
|
(1)
|
(4)
|
(3)
|
(3)
|
(7)
|
(6)
|
(15)
|
(24)
|
(25)
|
(23)
|
(16)
|
(10)
|
|
Pre-Tax Income |
360
N/A
|
393
+9%
|
409
+4%
|
443
+8%
|
505
+14%
|
633
+25%
|
684
+8%
|
978
+43%
|
1 148
+17%
|
1 319
+15%
|
1 487
+13%
|
1 453
-2%
|
1 629
+12%
|
1 911
+17%
|
1 945
+2%
|
1 988
+2%
|
1 916
-4%
|
1 666
-13%
|
1 777
+7%
|
1 832
+3%
|
1 780
-3%
|
1 838
+3%
|
|
Net Income | |||||||||||||||||||||||
Tax Provision |
(61)
|
(60)
|
(63)
|
(69)
|
(79)
|
(102)
|
(112)
|
(138)
|
(169)
|
(172)
|
(197)
|
(225)
|
(244)
|
(291)
|
(324)
|
(350)
|
(356)
|
(314)
|
(311)
|
(261)
|
(237)
|
(256)
|
|
Income from Continuing Operations |
300
|
333
|
345
|
373
|
426
|
531
|
572
|
841
|
980
|
1 147
|
1 291
|
1 228
|
1 385
|
1 620
|
1 620
|
1 638
|
1 560
|
1 352
|
1 465
|
1 571
|
1 542
|
1 582
|
|
Income to Minority Interest |
0
|
0
|
1
|
5
|
11
|
17
|
23
|
24
|
28
|
25
|
26
|
31
|
39
|
41
|
44
|
44
|
22
|
22
|
8
|
4
|
10
|
19
|
|
Net Income (Common) |
300
N/A
|
333
+11%
|
346
+4%
|
378
+9%
|
437
+16%
|
547
+25%
|
595
+9%
|
865
+45%
|
1 008
+17%
|
1 172
+16%
|
1 317
+12%
|
1 258
-4%
|
1 423
+13%
|
1 661
+17%
|
1 664
+0%
|
1 682
+1%
|
1 582
-6%
|
1 375
-13%
|
1 474
+7%
|
1 575
+7%
|
1 553
-1%
|
1 601
+3%
|
|
EPS (Diluted) |
0.51
N/A
|
0.56
+10%
|
0.54
-4%
|
0.57
+6%
|
0.68
+19%
|
0.83
+22%
|
0.75
-10%
|
1.09
+45%
|
1.27
+17%
|
1.48
+17%
|
1.66
+12%
|
1.05
-37%
|
1.19
+13%
|
0.91
-24%
|
1.4
+54%
|
1.41
+1%
|
0.89
-37%
|
0.77
-13%
|
0.83
+8%
|
2.69
+224%
|
0.87
-68%
|
0.9
+3%
|